Profile
Mr. Michal Fisher is an Independent Director at CNS Pharmaceuticals, Inc. and a Chief Business Officer at BioGenCell Ltd. He is on the Board of Directors at CNS Pharmaceuticals, Inc. Mr. Fisher was previously employed as a Head-Corporate Development by LifeSci Partners.
He received his undergraduate degree from Bar-Ilan University and a graduate degree from Bar-Ilan University.
Michal Fisher active positions
| Companies | Position | Start |
|---|---|---|
| CNS PHARMACEUTICALS, INC. | Director/Board Member | 2026-05-03 |
BioGenCell Ltd.
BioGenCell Ltd. BiotechnologyHealth Technology Develops cellular therapies that treat blood flow problems | Corporate Officer/Principal | - |
Former positions of Michal Fisher
| Companies | Position | End |
|---|---|---|
LifeSci Partners
LifeSci Partners Miscellaneous Commercial ServicesCommercial Services Operates as an integrated life sciences consulting platform that offers investor relations, investment banking, communications and strategy consulting | Corporate Officer/Principal | 2025-01-01 |
Training of Michal Fisher
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Bar-Ilan University
Bar-Ilan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioGenCell Ltd.
BioGenCell Ltd. BiotechnologyHealth Technology Develops cellular therapies that treat blood flow problems | Health Technology |
CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical drugs | Health Technology |
LifeSci Partners
LifeSci Partners Miscellaneous Commercial ServicesCommercial Services Operates as an integrated life sciences consulting platform that offers investor relations, investment banking, communications and strategy consulting | Commercial Services |
- Stock Market
- Insiders
- Michal Fisher
















